The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates, of which four drug candidates are in Phase III stage, 21 drug candidates are in Phase II stage, 20 drug candidates are in Phase I stage, 11 drug candidates are in Pre-Clinical stage and one drug candidates is in the Discovery stage.

1. GLOBAL INDUSTRY INSIGHT:
Systemic Lupus Erythematosus Pipeline Analysis, 2017 - Clinical Trials &
Results, Patent, Designation, Collaboration, and Other Developments

2. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug
candidates, of which four drug candidates are in Phase III stage, 21 drug candidates are in Phase
II stage, 20 drug candidates are in Phase I stage, 11 drug candidates are in Pre-Clinical stage and
one drug candidates is in the Discovery stage. Systemic lupus erythematosus is a type of lupus in
which the immune system damages its own tissues. The disease affects many parts of the body
including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is
caused by impaired immune system due to which the immune system attacks its own tissues and
can cause widespread inflammation and tissue damage in the affected organs. Some of the
common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart
problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes,
fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a
combination approach as number of organs are involved. Therefore, various combination therapies
are being used to improve quality of life of the patients. Also, combining novel drugs against
different organs as well as combination of drugs with biological and biochemical agents may further
enhance the treatment quality.
Explore Report at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-
erythematosus-pipeline-analysis
As per the findings of the research, around 25.0% of drug candidates of systemic lupus
erythematosus pipeline are being developed to be administered by subcutaneous route, 19.0% by
oral route, 17.0% by intravenous route and 14.0% are to be administered by other routes which
includes topical, infusion and intramuscular.
Many companies are involved in the development of systemic lupus erythematosus pipeline, with
their products in different phases. Anthera Pharmaceuticals, Inc. and AstraZeneca plc have their
drug candidates in the Phase III stage of development. Janssen Research & Development, LLC has
three drug candidates out of which one is in Phase II stage of development and two are in Phase I
stage of development. Merck KGaA also has two drug candidates in Phase II stage of development.
Redx Pharma plc has two drug candidates in Pre-Clinical stage of development.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-
erythematosus-pipeline-analysis/report-sample
© P&S Market Research. All rights reserved 2

3. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the
development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The
technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus
synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely
bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.
The research also found that various companies have collaborated for the development of systemic
lupus erythematosus pipeline. In October 2015, XTL Biopharmaceuticals Ltd. announced an
agreement with Yeda Research and Development Company Ltd. to amend the development
milestones in the license agreement signed between the parties in January 2014 for the
development of hCDR1, for the treatment of systemic lupus erythematosus. In September 2010,
Bristol-Myers Squibb Company and ZymoGenetics, Inc. signed a definitive agreement providing for
the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.
Pre-Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-
url=systemic-lupus-erythematosus-pipeline-analysis
Some of the key players developing drugs for systemic lupus erythematosus include Anthera
Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA, Eli Lilly and Company, Janssen Research &
Development, LLC, Redx Pharma plc and AstraZeneca plc.
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline analysis by phase
1.3.2 Pipeline analysis by route of administration
1.3.3 Pipeline analysis by target
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
© P&S Market Research. All rights reserved 3

4. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
2.2.1 Breakdown of primary research respondents
2.2.1.1 By industry participant
2.2.1.2 By company type
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.2.1 Biomarker identification
4.2.2 Developing combination therapies
4.3 Key Barriers
4.3.1 Alternative targets
4.3.2 Complex mechanism of action
4.4 Systemic Lupus Erythematosus Pipeline Analysis
4.4.1 Pipeline analysis by phase
4.4.2 Pipeline analysis by target
4.4.3 Pipeline analysis by route of administration
4.4.4 Pipeline analysis by company
Chapter 5. Systemic Lupus Erythematosus Pipeline Analysis by Phase (2017)
5.1 Phase III
5.1.1 Anifrolumab
5.1.1.1 Clinical trials
5.1.1.2 Clinical results
5.1.2 Blisibimod
5.1.2.1 Clinical trials
5.1.2.2 Strategic development
5.1.3 Epratuzumab
© P&S Market Research. All rights reserved 4

5. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
5.1.3.1 Clinical trials
5.1.3.2 Strategic development
5.1.3.3 Designation
5.1.4 Forigerimod
5.1.4.1 Clinical trials
5.1.4.2 Strategic development
5.1.4.3 Designation
5.2 Phase II
5.2.1 Ajulemic acid
5.2.1.1 Clinical trials
5.2.1.2 Strategic development
5.2.2 Atacicept
5.2.2.1 Clinical trials
5.2.2.2 Strategic development
5.2.3 Baricitinib
5.2.3.1 Clinical trials
5.2.4 BIIB059
5.2.4.1 Clinical trials
5.2.5 Brentuximab vedotin
5.2.5.1 Clinical trials
5.2.5.2 Technology
5.2.6 BT063
5.2.6.1 Clinical trials
5.2.7 Cenerimod
5.2.7.1 Clinical trials
5.2.8 Dapirolizumab Pegol (DZP)
© P&S Market Research. All rights reserved 5

6. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
5.2.8.1 Clinical trials
5.2.9 Edratide
5.2.9.1 Clinical trials
5.2.9.2 Clinical results
5.2.9.3 Strategic development
5.2.9.4 Designation
5.2.9.5 Patent
5.2.10 GDC-0853
5.2.10.1 Clinical trials
5.2.11 Iberdomide hydrochloride
5.2.11.1 Clinical trials
5.2.12 IFNα-Kinoid
5.2.12.1 Clinical trials
5.2.12.2 Strategic development
5.2.12.3 Designation
5.2.12.4 Patent
5.2.12.5 Technology
5.2.13 ILT-101
5.2.13.1 Clinical trials
5.2.14 Lulizumab pegol
5.2.14.1 Clinical trials
5.2.14.2 Patent
5.2.15 M2951
5.2.15.1 Clinical trials
5.2.16 RC18
5.2.16.1 Clinical trials
© P&S Market Research. All rights reserved 6

7. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
5.2.17 RSLV-132
5.2.17.1 Clinical trials
5.2.17.2 Strategic development
5.2.18 TAB08
5.2.18.1 Clinical trials
5.2.19 Ustekinumab
5.2.19.1 Clinical trials
5.2.19.2 Strategic development
5.2.20 Vobarilizumab
5.2.20.1 Clinical trials
5.2.20.2 Strategic development
5.2.21 XmAb5871
5.2.21.1 Clinical trials
5.2.21.2 Technology
5.3 Phase I
5.3.1 AGS-009
5.3.1.1 Clinical trials
5.3.1.2 Technology
5.3.2 AIC-284
5.3.3 Ala-Cpn10
5.3.3.1 Clinical trials
5.3.3.2 Strategic development
5.3.4 AMG 557
5.3.4.1 Clinical trials
5.3.4.2 Strategic development
5.3.5 AMG 570
© P&S Market Research. All rights reserved 7

8. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
5.3.5.1 Clinical trials
5.3.5.2 Strategic development
5.3.6 Amiselimod hydrochloride
5.3.6.1 Clinical trials
5.3.7 CKD-506
5.3.8 Dalazatide
5.3.8.1 Strategic development
5.3.9 GSK2646264
5.3.9.1 Clinical trials
5.3.10 JNJ-55920839
5.3.10.1 Clinical trials
5.3.11 JNJ-56022473
5.3.11.1 Clinical trials
5.3.12 MEDI0700
5.3.13 MEDI-7734
5.3.13.1 Clinical trials
5.3.13.2 Strategic development
5.3.14 MGD-010
5.3.14.1 Clinical trials
5.3.14.2 Clinical results
5.3.14.3 Technology
5.3.15 Milatuzumab
5.3.15.1 Clinical trials
5.3.15.2 Grant
5.3.16 PF-06823859
5.3.16.1 Clinical trials
© P&S Market Research. All rights reserved 8

9. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
5.3.17 SAR113244
5.3.17.1 Clinical trials
5.3.18 SKI-O-703
5.3.18.1 Clinical trials
5.3.18.2 Patent
5.3.19 TAK-079
5.3.19.1 Clinical trials
5.3.20 Venetoclax
5.3.20.1 Clinical trials
5.3.20.2 Clinical results
5.4 Pre-Clinical
5.4.1 BB-004
5.4.1.1 Technology
5.4.2 BTK Inhibitor
5.4.3 DMXD-011
5.4.4 GNKS356
5.4.4.1 Strategic development
5.4.4.2 Technology
5.4.5 Hyper-sialylated IVIg (hsIVIg)
5.4.5.1 Technology
5.4.6 Immunoproteasome Inhibitor Program
5.4.7 INX-021
5.4.7.1 Strategic development
5.4.8 KPT-350
5.4.8.1 Grant
5.4.8.2 Technology
© P&S Market Research. All rights reserved 9

10. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
5.4.9 Porcupine Inhibitor
5.4.10 SBI-9674
5.4.10.1 Strategic development
5.4.10.2 Technology
5.4.11 VISTA Agonist
5.4.11.1 Strategic development
5.4.11.2 Grant
5.5 Discovery
5.5.1 Annexuzlimab
5.5.1.1 Strategic development
5.5.1.2 Financing
Chapter 6. Competitive Landscape
6.1 Key Players Benchmarking for Systemic Lupus Erythematosus Drug Candidates
6.2 SWOT Analysis of Systemic Lupus Erythematosus Pipeline
Chapter 7. Company Profiles
7.1 Anthera Pharmaceuticals, Inc.
7.1.1 Business overview
7.1.2 Product and service offerings
7.2 AstraZeneca plc
7.2.1 Business overview
7.2.2 Product and service offerings
7.3 Eli Lilly & Company
7.3.1 Business overview
7.3.2 Product and service offerings
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Business overview
© P&S Market Research. All rights reserved 10

11. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
7.4.2 Product and service offerings
7.5 Redx Pharma Plc
7.5.1 Business overview
7.5.2 Product and service offerings
7.6 Merck KGaA
7.6.1 Business overview
7.6.2 Product and service offerings
7.7 Johnson & Johnson
7.7.1 Business overview
7.7.2 Product and service offerings
7.8 GlaxoSmithKline plc
7.8.1 Business overview
7.8.2 Product and service offerings
7.9 Bristol-Myers Squibb Company
7.9.1 Business overview
7.9.2 Product and service offerings
Chapter 8. Appendix
8.1 Abbreviations
Browse Other Related Report at: https://www.psmarketresearch.com/industry-
report/pharmaceuticals
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting
services for various geographies around the globe. We provide market research reports, industry
forecasting reports, business intelligence, and research based consulting services across different
industry/business verticals.
© P&S Market Research. All rights reserved 11

12. Systemic Lupus Erythematosus Exhibits Emerging Pipeline with
50+ Drug Candidates
As one of the top growing market research agency, we’re keen upon providing market landscape
and accurate forecasting. Our analysts and consultants are proficient with business intelligence and
market analysis, through their interaction with leading companies of the concerned domain. We
help our clients with B2B market research and assist them in identifying various windows of
opportunity, and framing informed and customized business expansion strategies in different
regions.
Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
© P&S Market Research. All rights reserved 12